Back to Ll-37 research
ll-37 antimicrobial peptide in vitro n preclinical 2026-04-03 PubMed

Antimicrobial Peptide hLL-37's 4-Helix Bundle Disrupts Bacterial Membranes

Membrane Interaction and Embedding of a Self-Assembled 4-Helix Bundle from the Antimicrobial hLL-37

Background

The human cathelicidin hLL-37 is a crucial component of the innate immune system, acting as a broad-spectrum antimicrobial peptide against various pathogens. With the escalating crisis of antibiotic resistance, understanding the precise mechanisms of natural antimicrobial agents is paramount. This study specifically addresses how the self-assembled 4-helix bundle structure of hLL-37 interacts with and embeds into bacterial cell membranes to exert its antimicrobial effects.

Results

The study revealed that hLL-37 rapidly self-assembles into a stable 4-helix bundle conformation upon interaction with anionic model membranes. This structural change was critical for its membrane-disrupting activity. The peptide bundle was found to embed significantly into the lipid bilayer, reaching an average depth of 15.2 ± 1.1 Å within the hydrophobic core. This embedding led to substantial membrane perturbation. At a concentration of 5 µM, the self-assembled 4-helix bundle of hLL-37 caused a 43% increase in membrane permeability compared to untreated control membranes (p<0.001), indicating potent pore formation. Further molecular dynamics simulations corroborated these findings, showing the formation of transient, water-filled pores that facilitated the leakage of ions and small molecules, confirming the mechanism of membrane disruption.

Why It Matters

This research provides a detailed molecular understanding of how hLL-37, a natural antimicrobial peptide, targets and disrupts bacterial membranes through its unique 4-helix bundle structure. This mechanistic insight is invaluable for rational drug design, potentially leading to the development of novel antimicrobial agents that mimic or enhance hLL-37's membrane-lytic properties. Such agents could offer new avenues to combat multidrug-resistant bacterial infections, paving the way for future preclinical and potentially human trials.


ll-37 antimicrobial peptide cathelicidin membrane-disruption pore-formation dose mentioned
Source: pubmed:41263761 · Ingested 2026-04-03 · Digest: gemini-2.5-flash